journal article·2025-04-04

Doxorubicin-Conjugated Terbium-Doped Carbon Dots for Site-Specific Colon Cancer Theranostics

Dhanavardhini Kalyanasundaram, Paul Matthew Arockia Sagayaraj, Tiasha Dasgupta, Tharani G R, Tamizhselvi Ramasamy, Anandh Sundaramoorthy, Nireekshana Nandigam, Kanniyappan Udayakumar, Venkat S. Kumar, Subramani Karthikeyan, Shanmugavel Chinnathambi, Ganesh N. Pandian, Andrews Nirmala Grace, Casimeer C. Sangeetha, Rajendiran Mangaiyarkarasi

ACS Applied Nano Materials· Volume 8· Issue 13
Publisher page

Abstract

This work focuses on synthesizing fluorescent rare earth terbium-doped carbon dots (CD-Tb) as a nanodrug carrier for doxorubicin (DOX) drug moieties using the hydrothermal method. The nature of CD-Tb nanoparticles in the absence and presence of DOX was evaluated using various spectroscopic and microscopic techniques, namely, X-ray diffraction (XRD), high-resolution transmission electron microscopy (HR-TEM), Zeta potential analyzer, Raman spectroscopy, X-ray photoelectron spectroscopy (XPS), UV–visible, fluorescence emission, and lifetime spectroscopy. The synthesized CD-Tb nanoparticles were found to be approximately 7 nm in size and spherical, with a surface charge of −20.7 mV. They are biocompatible with electron-rich amino groups on their surface and are used for the bioconjugation of DOX, an anticancer drug. The photophysical characterization shows 92.5% of adsorption and 89% of in vitro release of DOX from CD-Tb nanoparticles. This might be due to the presence of carboxyl and amino groups on the DOX surface and CD-Tb nanoparticles. The effective concentration of CD-Tb nanoparticles and DOX was achieved at a stoichiometric ratio of 1:1.5. Further, the Stern–Volmer quenching rate constant ( K q ) of CD-Tb-DOX was calculated as 4.9 × 10 10 L/mol·s –1, and the binding of nanoparticles with various concentrations of DOX is found to be static. In addition, the in vitro antitumoral activity of free DOX and the CD-Tb-DOX against Caco-2 cancer cell lines (human colon cancer) and L929 cell lines (mouse fibroblast cells) was evaluated as the healthy cell model. CD-Tb-DOX’s in vitro cytotoxic evaluation result shows higher cytotoxicity and morphological changes at Caco-2 colon cancer tumor sites than free DOX. In brief, this study confirms that the synthesized CD-Tb-DOX nanocarriers could significantly enhance the metabolic damage in the Caco-2 cancer cell lines (human colon cancer) and facilitate the action of cellular apoptosis, which might be helpful in site-specific targeting drug delivery applications.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Carbon and Quantum Dots Applications · Nanocluster Synthesis and Applications · Advanced Nanomaterials in Catalysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Centre for Nanotechnology Research

Vellore Institute of Technology

School of Bioscience and Technology

Department of Medical Physics

Anna University

Institute of Biomedical Engineering, Canada Research Center, CHU Sainte-Justine

University of Montréal

Centre for Healthcare Advancement, Innovation and Research, Vellore Institute of Technology, Vandalur, Chennai 600048, India

Institute for Integrated Cell-Material Sciences, Institute for Advanced Study

Kyoto University

Sri Padavati Mahila Visvavidyalayam (Women’s University)

Funding

Science and Engineering Research Board · VIT University · Japan Society for the Promotion of Science

References (47)

Show source-provided references
1. 10.1016/j.adcanc.2024.10011410.1016/j.adcanc.2024.100114 ↗
2. 10.1021/acsanm.3c0546410.1021/acsanm.3c05464 ↗
3. 10.1111/cpr.1248810.1111/cpr.12488 ↗
4. 10.1016/j.biopha.2014.11.02310.1016/j.biopha.2014.11.023 ↗
5. 10.3389/fchem.2023.122784310.3389/fchem.2023.1227843 ↗
6. 10.1038/s41598-018-19373-310.1038/s41598-018-19373-3 ↗
7. 10.1016/j.mtcomm.2022.10459010.1016/j.mtcomm.2022.104590 ↗
8. 10.1088/1748-605X/ad7f3a10.1088/1748-605X/ad7f3a ↗
9. 10.1039/C9TB00032A10.1039/C9TB00032A ↗
10. 10.1007/s11095-020-02852-610.1007/s11095-020-02852-6 ↗
11. 10.1021/acsami.1c0990910.1021/acsami.1c09909 ↗
12. 10.1039/C6RA28345D10.1039/C6RA28345D ↗
13. 10.2147/IJN.S22915410.2147/IJN.S229154 ↗
14. 10.1039/c3tb21151g10.1039/c3tb21151g ↗
15. 10.1016/j.jhazmat.2020.12260610.1016/j.jhazmat.2020.122606 ↗
16. 10.1007/s00604-018-2953-910.1007/s00604-018-2953-9 ↗
17. 10.1016/j.ccr.2016.02.01710.1016/j.ccr.2016.02.017 ↗
18. 10.1021/nn401911k10.1021/nn401911k ↗
19. 10.1021/cr00051a00410.1021/cr00051a004 ↗
20. 10.1103/PhysRevB.67.05440310.1103/PhysRevB.67.054403 ↗
21. 10.1007/s40684-014-0019-y10.1007/s40684-014-0019-y ↗
22. 10.1134/S001250082204002410.1134/S0012500822040024 ↗
23. 10.1007/978-1-4939-6788-9_2110.1007/978-1-4939-6788-9_21 ↗
24. 10.1016/j.chembiol.2020.07.00910.1016/j.chembiol.2020.07.009 ↗
25. 10.1364/BOE.2.00080510.1364/BOE.2.000805 ↗
26. 10.1021/acsnano.9b0813310.1021/acsnano.9b08133 ↗
27. 10.1038/srep4048610.1038/srep40486 ↗
28. 10.1016/j.arabjc.2023.10484110.1016/j.arabjc.2023.104841 ↗
29. 10.1016/j.foodchem.2020.12662410.1016/j.foodchem.2020.126624 ↗
30. 10.1016/j.jlumin.2022.11873210.1016/j.jlumin.2022.118732 ↗
31. 10.1088/2050-6120/aa5e2b10.1088/2050-6120/aa5e2b ↗
32. 10.1021/acsomega.2c0660010.1021/acsomega.2c06600 ↗
33. 10.1016/j.microc.2023.10967010.1016/j.microc.2023.109670 ↗
34. 10.3390/cells1007171710.3390/cells10071717 ↗
35. 10.1039/D0NR01236J10.1039/D0NR01236J ↗
36. 10.3390/nano807053210.3390/nano8070532 ↗
37. 10.1007/s10854-017-8229-z10.1007/s10854-017-8229-z ↗
38. 10.1021/acsomega.1c0550010.1021/acsomega.1c05500 ↗
39. 10.3390/polym1420427610.3390/polym14204276 ↗
40. 10.1039/C7RA07002K10.1039/C7RA07002K ↗
41. 10.1021/acsomega.8b0115910.1021/acsomega.8b01159 ↗
42. 10.1021/acsomega.2c0148210.1021/acsomega.2c01482 ↗
43. 10.1021/acs.jpclett.9b0389110.1021/acs.jpclett.9b03891 ↗
44. 10.18632/oncotarget.534410.18632/oncotarget.5344 ↗
45. 10.1155/2010/78017110.1155/2010/780171 ↗
46. 10.1007/s00412-017-0654-510.1007/s00412-017-0654-5 ↗
47. 10.1038/s41392-020-00342-010.1038/s41392-020-00342-0 ↗